BackClearPoint Neuro Overview

ClearPoint Neuro EBIT

ClearPoint Neuro's EBIT is $-31M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$10.24M
80.35% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$31.04M
37.24% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

ClearPoint Neuro (CLPT) FAQ

As of the most recent data (June 2026), CLPT shows a EBIT of $-31M. That compares with $-23M in the prior-year period — down 37.2% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CLPT's EBIT is now $-31M (was $-23M) — a 37.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ClearPoint Neuro is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. ClearPoint Neuro is at $-31M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how CLPT stacks up against individual peers as well.

Tracking CLPT's ebit over time shows whether ClearPoint Neuro is scaling, shrinking, or reshaping that part of the business. The current reading is $-31M That compares with $-23M in the prior-year period — down 37.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has ClearPoint Neuro's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-31M) with ownership activity and broader fundamentals.